LoginRegister

    Wockhardt gets zero USFDA observations for Bioequivalence centre

    Medical Dialogues BureauWritten by Medical Dialogues Bureau   |  
    Wockhardt gets zero USFDA observations for Bioequivalence centre

    Bioequivalence studies of Tamsulosin 0.4mg capsules and Metoprolol Tartrate 200mg ER tablets were audited, Wockhardt had reported.


    New Delhi: Shares of drugmaker Wockhardt Ltd rise as much as 2.3 per cent to Rs 460, their highest since April 8.


    The company says no observations made after the USFDA inspects its Bioequivalence centre in Aurangabad, Maharashtra.


    Bioequivalence studies of Tamsulosin 0.4mg capsules and Metoprolol Tartrate 200mg ER tablets were audited, the company had reported.


    Read Also: Wockhardt gets USFDA nod for Decitabine injection to treat cancer


    About 425,970 shares change hands in less than half an hour into trading compared with the 30-day average volume of around 1.9 million.


    Headquartered in Mumbai, the company has manufacturing plants in India, UK, Ireland, France and the US, and subsidiaries in the US, UK, Ireland and France.


    It is a global company with more than half of its revenue coming from Europe. The company was founded by Dr Habil Khorakiwala in the 1960s


    Read Also: Wockhardt gets USFDA nod for Abiraterone Acetate to treat prostate cancer

    aurangabadBioequivalence centre AurangabadmetoprololMetoprolol Tartrate tabletspharmapharma newsTamsulosinTamsulosin capsulestartrateUSFDAUSFDA inspectionWockhardtWockhardt shares
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X